Effective November 7, 2005, CDEX Inc. ("the Company") entered into a strategic distribution agreement ("Agreement) with Baxa Corporation ("Baxa"). The Agreement provides for Baxa to be the exclusive distributor of CDEX's ValiMed(TM) solution for medication verification for healthcare organizations in the United States and Canada. Based on market experience and knowledge gained in 2006, the parties entered into an Amendment to Reseller Agreement ("Amendment) effective January 30, 2007 to strengthen their relationship and the distribution of Valimed (TM). The Amendment specifies the base pack of drug signatures to be installed on Valimed(TM) units and provides a process and terms for additional signatures, provides a fixed schedule for delivery, and waives Baxa's purchase requirements to maintain distribution exclusivity.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.